Amicus Therapeutics Inc. (NASDAQ:FOLD) traded up 3% on Wednesday . The stock traded as high as $7.74 and last traded at $7.59, with a volume of 1,119,253 shares traded. The stock had previously closed at $7.37.

Several equities research analysts have weighed in on the company. Bank of America Corp. assumed coverage on Amicus Therapeutics in a research report on Wednesday, May 18th. They issued a “buy” rating and a $10.00 target price on the stock. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Leerink Swann reissued an “outperform” rating and set a $17.00 price target on shares of Amicus Therapeutics in a report on Wednesday, June 1st. Finally, Chardan Capital set a $15.00 price target on Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. Amicus Therapeutics currently has a consensus rating of “Buy” and an average target price of $12.19.

The firm’s 50-day moving average is $6.46 and its 200 day moving average is $6.87. The stock’s market capitalization is $1.02 billion.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. Equities analysts forecast that Amicus Therapeutics Inc. will post ($1.35) EPS for the current fiscal year.

In other Amicus Therapeutics news, insider Jay Barth sold 20,916 shares of Amicus Therapeutics stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $7.00, for a total value of $146,412.00. Following the completion of the transaction, the insider now owns 25,458 shares in the company, valued at approximately $178,206. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Ellen Rosenberg acquired 15,000 shares of the business’s stock in a transaction on Thursday, June 2nd. The stock was acquired at an average price of $7.67 per share, with a total value of $115,050.00. The disclosure for this purchase can be found here.

Other institutional investors have modified their holdings of the company. RS Investment Management Co. LLC increased its position in shares of Amicus Therapeutics by 22.0% in the fourth quarter. RS Investment Management Co. LLC now owns 3,488,863 shares of the biopharmaceutical company’s stock valued at $33,842,000 after buying an additional 628,438 shares during the last quarter. Jennison Associates LLC increased its position in shares of Amicus Therapeutics by 3.3% in the fourth quarter. Jennison Associates LLC now owns 4,123,955 shares of the biopharmaceutical company’s stock valued at $40,002,000 after buying an additional 133,138 shares during the last quarter. California Public Employees Retirement System increased its position in shares of Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock valued at $3,163,000 after buying an additional 11,600 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock valued at $1,360,000 after buying an additional 5,100 shares during the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.